PMID- 28618047
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20180723
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 71
IP  - 6
DP  - 2017 Dec
TI  - Focal beta-catenin mutation identified on formalin-fixed and paraffin-embedded 
      inflammatory hepatocellular adenomas.
PG  - 989-993
LID - 10.1111/his.13283 [doi]
AB  - The identification of hepatocellular adenoma (HCA) with mutation in exon 3 of the 
      CTNNB1 gene encoding for beta-catenin is clinically relevant due to a higher risk of 
      malignant transformation. Inflammatory HCA (IHCA) can exhibit beta-catenin 
      activation (beta-IHCA). We report two cases with multiple IHCA in which focal 
      beta-catenin activation has been found in one of the IHCA. In both cases, the 
      diagnosis of IHCA was confirmed on the resected nodules by routine stains, 
      immunohistochemical detection of C-reactive protein (CRP) and molecular biology 
      on frozen material. An additional molecular analysis was performed on 
      formalin-fixed paraffin-embedded (FFPE) material that showed focal glutamine 
      synthetase (GS) staining, the surrogate marker of beta-catenin activation. In case 
      1, it was a 1.8-cm area within the 7.5 cm IHCA, and in case 2 a small 0.3-cm area 
      within a 1.8 cm resected IHCA located close to a larger IHCA, negative for GS. In 
      both cases, nuclear beta-catenin expression and decreased reticulin network were 
      observed in the GS expressing foci, together with cholestasis and diffuse CD34 
      expression in case 1. Molecular analysis by pyrosequencing on FFPE material using 
      the GS-stained slides as reference to select areas with/without positive staining 
      revealed a CTNNB1 exon 3 mutation restricted to the areas exhibiting both 
      positive GS and CRP expression, whereas wild-type CTNNB1 was found in areas 
      showing only CRP staining. These two cases illustrate focal beta-catenin activation 
      that can occur within IHCAs. Additional data are needed to determine if beta-catenin 
      mutation is a secondary event in IHCA.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Saldarriaga, Joan
AU  - Saldarriaga J
AD  - Service of Clinical Pathology, Lausanne University Hospital, Institute of 
      Pathology, Lausanne, Switzerland.
FAU - Bisig, Bettina
AU  - Bisig B
AD  - Service of Clinical Pathology, Lausanne University Hospital, Institute of 
      Pathology, Lausanne, Switzerland.
FAU - Couchy, Gabrielle
AU  - Couchy G
AD  - Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris 
      Diderot, Paris, France.
FAU - Castain, Claire
AU  - Castain C
AD  - Service de Pathologie, Hopital Pellegrin, CHU Bordeaux, Bordeaux, France.
FAU - Zucman-Rossi, Jessica
AU  - Zucman-Rossi J
AD  - Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris 
      Diderot, Paris, France.
FAU - Balabaud, Charles
AU  - Balabaud C
AD  - Inserm UMR 1053, Universite Bordeaux, Bordeaux, France.
FAU - Sempoux, Christine
AU  - Sempoux C
AD  - Service of Clinical Pathology, Lausanne University Hospital, Institute of 
      Pathology, Lausanne, Switzerland.
FAU - Bioulac-Sage, Paulette
AU  - Bioulac-Sage P
AUID- ORCID: 0000-0001-5952-0623
AD  - Service de Pathologie, Hopital Pellegrin, CHU Bordeaux, Bordeaux, France.
AD  - Inserm UMR 1053, Universite Bordeaux, Bordeaux, France.
LA  - eng
PT  - Journal Article
DEP - 20171006
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (beta Catenin)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 6.3.1.2 (Glutamate-Ammonia Ligase)
SB  - IM
MH  - Adenoma, Liver Cell/*genetics/pathology
MH  - Adult
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Cell Transformation, Neoplastic
MH  - Female
MH  - Formaldehyde
MH  - Glutamate-Ammonia Ligase/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Liver Neoplasms/*genetics/pathology
MH  - Microdissection
MH  - Middle Aged
MH  - Mutation
MH  - Paraffin Embedding
MH  - beta Catenin/*genetics/metabolism
OTO - NOTNLM
OT  - C-reactive protein
OT  - exon3 CTNNB1 mutation
OT  - glutamine synthetase
OT  - malignant transformation
OT  - microdissection
EDAT- 2017/06/16 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/06/16 06:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/06/10 00:00 [accepted]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/06/16 06:00 [entrez]
AID - 10.1111/his.13283 [doi]
PST - ppublish
SO  - Histopathology. 2017 Dec;71(6):989-993. doi: 10.1111/his.13283. Epub 2017 Oct 6.